Contemporary Management of HIV 2021: New Data From IAS 2021—Audio Recap, Part 2

In this second of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including data on investigational antiretroviral agents, lenacapavir and islatravir, and alternative dosing of BPaL for MDR-TB.  This episode includes discussion of:An extension of FLAIR, demonstrating virologic efficacy and safety of long-acting CAB plus RPV at Week 124A Week 26 safety and efficacy analysis of CAPELLA, a study of lenacapavir in heavily treatment–experienced PWHCALIBRATE, a study of the safety and efficacy of lenacapavir in treatment-naive PWHA Week 96 safety analysis of Protocol 011, evaluating islatravir plus DOR in treatment-naive patientsA Week 24 safety and pharmacokinetic analysis of Protocol 016, evaluating oral islatravir once monthly for PrEPZeNix, a phase III trial of pretomanid, bedaquiline, and linezolid (BPaL) in patients with highly resistant TBPresenters:Eric S. Daar, MDChief, Division of HIV MedicineHarbor-UCLA Medical CenterProfessor of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaShobha Swaminathan, MDAssociate ProfessorDivision of Infectious Diseases  Department of MedicineRutgers New Jersey Medical SchoolNewark, New JerseyFollow along with the slides at:https://bit.ly/3hvRN5bContent based on an online CME program supported by an educational grant from ViiV Healthcare. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.